Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirum Pharmaceuticals Inc (NQ: MIRM ) 40.72 +0.27 (+0.67%) Official Closing Price Updated: 4:15 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 271,737 Open 39.69 Bid (Size) 40.80 (2) Ask (Size) 41.50 (4) Prev. Close 40.45 Today's Range 38.16 - 41.00 52wk Range 23.14 - 45.23 Shares Outstanding 38,297,975 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 November 04, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting October 31, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Performance YTD +35.64% +35.64% 1 Month +5.08% +5.08% 3 Month +4.01% +4.01% 6 Month +57.16% +57.16% 1 Year +38.74% +38.74% More News Read More Analyst Expectations For Mirum Pharmaceuticals's Future October 11, 2024 Via Benzinga Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis October 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences August 28, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024 August 07, 2024 Via InvestorPlace Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update August 07, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 July 31, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older July 25, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC July 08, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX June 28, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday June 18, 2024 Via Benzinga Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 17, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session June 17, 2024 Via Benzinga Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies June 17, 2024 Via Benzinga Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday June 17, 2024 Via Benzinga Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies June 17, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 June 16, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress June 06, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
